Alta Partners
Alta Partners is a venture capital firm investing in the healthcare and life sciences sector.
Business Model:
Revenue: $5M
Employees: 11-50
Rankings
Industries / Tags:
Detailed Alta Partners Information
Geographic Data
Address: 1 Embarcadero Ctr
City: San Francisco
State: CA
Zip: 94111
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$405M
Social
Twitter
Linkedin
Crunchbase
Metrics
5,209,985Website Global Rank
1,756Website Monthly Traffic
Twitter Followers
Description
Alta Partners is a venture capital firm investing in the healthcare and life sciences sector. Their diverse and integrated team brings together a powerful depth of knowledge and experience, delivering tangible results for their companies and their investors.
Contact Phone:
+14153624022
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2020 | Lassen Therapeutics | Series A | 31M |
| 5/2007 | Arete Therapeutics | Series A | 35M |
| 6/2010 | Calistoga Pharmaceuticals | Series C | 40M |
| 7/2003 | Xelerated Holdings | Venture Round | 12.5M |
| 1/2013 | Carbylan Therapeutics | Venture Round | 6M |
| 10/2002 | nCircle Network Security | Series C | 0 |
| 10/2005 | OPAL Therapeutics | Series A | 6M |
| 8/2014 | St. George&s;s University | Private Equity Round | 750M |
| 6/2001 | Aevi Genomic Medicine | Series A | 7M |
| 8/2007 | Corcept | Post-IPO Equity | 10.1M |
| 3/2006 | Aegis Semiconductor | Series D | 8M |
| 3/2006 | Aegis Lightwave | Series D | 8M |
| 12/2003 | USGI Medical | Series B | 12M |
| 2/2011 | Chimerix | Series F | 45M |
| 4/2005 | Xelerated | Series C | 17M |
| 7/2002 | Anesiva | Series C | 50.4M |
| 9/2014 | Allakos | Series A | 10M |
| 1/2017 | GenePeeks | Series B | 0 |
| 9/2022 | Allakos | Post-IPO Equity | 0 |
| 1/1999 | Arrow Therapeutics | Seed Round | 1.7M |
| 3/2003 | Tacit Software | Series C | 3.1M |
| 2/2007 | Proacta | Series B | 35M |
| 12/1997 | Genteric | Series A | 9M |
| 8/2004 | Ceregene | Series B | 32M |
| 5/2009 | Neothetics | Series A | - |
| 7/2003 | Xelerated | Venture Round | 12.5M |
| 6/2010 | Virobay | Venture Round | 10M |
| 1/2010 | Virobay | Debt Financing | 300k |
| 7/2014 | Virobay | Series B | 8M |
| 12/2006 | SARcode Bioscience | Venture Round | 29M |
| 12/2004 | CymaBay Therapeutics | Series B | 44M |
| 4/2007 | TransMedics | Series D | 0 |
| 2/2004 | Nanomix | Series B | 5M |
| 12/2009 | Coapt Systems | Debt Financing | 3.7M |
| 7/2007 | Agensys | Series D | 41.3M |
| 10/2009 | Corcept | Post-IPO Equity | 18M |
| 1/2019 | Vir Biotechnology | Series B | 327.6M |
| 3/2013 | Achaogen | Series D | 18.9M |
| 1/2002 | NeurogesX | Series B | 22.9M |
| 1/2020 | Novome Biotechnologies | Series A | 0 |
| 8/2018 | Everside Health | Growth | 165M |
| 3/2007 | Coapt Systems | Series E | 22.6M |
| 1/2009 | 7TM Pharma | Venture Round | 0 |
| 1/2008 | Calistoga Pharmaceuticals | Series A | 5.2M |
| 2/2021 | PatientsLikeMe | Venture Round | 0 |
| 3/2009 | Sutro Biopharma | Series B | 15M |
| 12/2007 | Sutro Biopharma | Series B | 21M |
| 4/2004 | Tacit Knowledge | Series A | 7M |
| 8/2007 | Nereus Pharmaceuticals | Series D | 0 |
| 10/2003 | Arrow Therapeutics | Series B | 34.9M |
| 3/2005 | TorreyPines Therapeutics | Series C | 0 |
| 10/2005 | Nereus Pharmaceuticals | Series D | 0 |
| 4/2004 | Ablynx | Series B | 30M |
| 5/2004 | Plexxikon | Series B | 0 |
| 5/2009 | Calistoga Pharmaceuticals | Series B | 30M |
| 5/2008 | Esperion | Series A | 22.8M |
| 4/2009 | Aerovance | Venture Round | 38M |
| 6/2003 | Intarcia Therapeutics | Series D | 43M |
| 12/2001 | USGI Medical | Series A | 3.5M |
| 5/2001 | AGY | Series B | 13M |
| 7/2011 | SARcode Bioscience | Series B | 44M |
| 1/2007 | SARcode Bioscience | Series A | 25M |
| 8/2005 | Alba Therapeutics | Series A | 30M |
| 2/2011 | VertiFlex | Venture Round | 14M |
| 7/2008 | Sierra Surgical | Series B | 14.5M |
| 8/2007 | Sierra Surgical | Series A | 7.1M |
| 8/2006 | ChemoCentryx | Series C | 0 |
| 5/2007 | Prolacta Bioscience | Series C | 0 |
| 1/2011 | PneumRx | Venture Round | 0 |
| 12/2013 | Sutro Biopharma | Series D | 0 |
| 5/2012 | Sutro Biopharma | Series C | 16.5M |
| 7/2018 | Sutro Biopharma | Series E | 0 |
| 6/2007 | 7TM Pharma | Series D | 22M |
| 3/2006 | 7TM Pharma | Series C | 0 |
| 10/2008 | ChemoCentryx | Series E | 50M |
| 2/2002 | Syntonix Pharmaceuticals | Series B | 35.8M |
| 1/2004 | TransMedics | Series B | 27.6M |
| 6/2007 | Paracor Medical | Series D | 44M |
| 5/2007 | nCircle Network Security | Venture Round | 5M |
| 8/2001 | nCircle Network Security | Series B | 0 |
| 11/2019 | EGenesis | Series B | 0 |
| 4/2002 | Dynavax Technologies | Series D | 0 |
| 7/2013 | aTyr Pharma | Series D | 49M |
| 10/2003 | Anesiva | Series D | 20M |
| 11/2012 | Kiadis Pharma | Venture Round | 0 |
| 3/2009 | Aegis Semiconductor | Series E | 3M |
| 6/2000 | NeurogesX | Series A | 8.4M |
| 12/2001 | R2 Technology | Venture Round | 0 |
| 3/2008 | SurgRx | Series G | 19.8M |
| 11/2006 | Intradigm Corporation | Series A | 16M |
| 12/2005 | NeurogesX | Series D | 20M |
| 3/2017 | EGenesis | Series A | 0 |
| 3/2007 | PneumRx | Series B | 0 |
| 6/2021 | ImmuneID | Series A | 0 |
| 11/2009 | CymaBay Therapeutics | Series E | 0 |
| 1/2017 | Vir Biotechnology | Venture Round | 150M |
| 2/2000 | Reef Point Systems | Venture Round | 22M |
| 7/2008 | MacroGenics | Series D | 12.5M |
| 4/2000 | Nereus Pharmaceuticals | Series A | 8.6M |
| 2/2006 | iSOCO | Venture Round | 357k |
| 11/2001 | Biovitrum | Venture Round | - |
| 3/2006 | TransMedics | Series C | 0 |
| 7/2003 | PamGene | Series B | 11.3M |
| 12/2002 | Arrow Therapeutics | Venture Round | 10.9M |
| 4/2010 | Achaogen | Series C | 56M |
| 5/2019 | DispatchHealth | Series B | 33M |
| 3/2002 | Agensys | Series C | 0 |
| 10/2008 | MacroGenics | Series D | 25M |
| 11/2022 | BetterVet | Series A | 40M |
| 3/2007 | ChemoCentryx | Series D | 29.8M |
| 11/2006 | Abionyx Pharma | Series B | 53.5M |
| 2/2006 | Netli | Venture Round | 18M |
| 9/2002 | Nanomix | Series B | 9M |
| 4/2007 | SurgRx | Series F | 20M |
| 8/2000 | ePhones | Series C | 10.5M |
| 11/2003 | Sanarus Medical | Series C | 19.1M |
| 7/2002 | Synad Technologies | Series B | 20.7M |
| 3/2004 | nCircle Network Security | Venture Round | 15M |
| 7/2001 | Tacit Software | Series C | 10M |
| 10/2008 | MAKO Surgical | Post-IPO Equity | 60M |
| 11/2010 | Sutro Biopharma | Series C | 36.5M |
| 3/2005 | Nanomix | Series C | 16M |
| 2/2014 | Neothetics | Series C | 8M |
| 12/2012 | Neothetics | Series C | 20.6M |
| 10/2013 | Immune Design | Series C | 49M |
| 4/2000 | Definity Health | Venture Round | 23M |
| 5/2004 | Aegis Semiconductor | Series C | 10M |
| 8/2010 | Taligen Therapeutics | Series B | 10M |
| 1/2002 | Renovis | Series B | 0 |
| 10/2020 | Be Biopharma | Series A | 52M |
| 7/2010 | Cara Therapeutics | Series D | 0 |
| 1/2002 | Coapt Systems | Series B | 6.3M |
| 6/2010 | Nereus Pharmaceuticals | Series E | 0 |
| 7/2022 | Everside Health | Venture Round | 0 |
| 4/2007 | aTyr Pharma | Series B | 10.5M |
| 3/2002 | Aegis Semiconductor | Series B | 16M |
| 10/2018 | CuraSen Therapeutics | Series A | 54.5M |
| 2/2007 | Chimerix | Series D | 23.1M |
| 1/2020 | Tyra Biosciences | Series A | 50M |
| 8/2008 | Xelerated | Series E | 0 |
| 5/2007 | Xelerated | Series D | 0 |
| 10/2012 | ZS Pharma | Series C | 0 |
| 12/2017 | Allakos | Series B | 100M |
| 5/2013 | Lumena Pharmaceuticals | Series A | 23M |
| 8/2009 | Chimerix | Series E | 16.1M |
| 3/2007 | Aerovance | Series C | 60M |
| 4/2009 | Sunesis Pharmaceuticals | Post-IPO Equity | 0 |
| 3/2014 | Lumena Pharmaceuticals | Series B | 45M |
| 1/2008 | Taligen Therapeutics | Series B | 65M |
| 3/2007 | Phenomix | Series C | 55M |
| 5/2013 | Kite Pharma | Series A | 20M |
| 6/2003 | Phenomix | Series A | 11.6M |
| 9/2001 | 7TM Pharma | Series A | 15M |
| 10/2005 | Radiant Medical | Venture Round | 36M |
| 11/2006 | Cara Therapeutics | Series C | 24M |
| 12/2012 | Evofem Biosciences | Series C | 20.6M |
| 6/2003 | CyThera | Venture Round | 2M |
| 7/1999 | Wavtrace | Venture Round | 24M |
| 6/2006 | Aegerion Pharmaceuticals | Series A | 22.5M |
| 2/2014 | Evofem Biosciences | Series C | 8M |
| 11/2007 | Aegerion Pharmaceuticals | Series B | 0 |
| 4/2000 | ProjectGuides.com | Series B | 6.3M |
| 10/2004 | 7TM Pharma | Series B | 7.6M |
| 12/2000 | PamGene | Series A | 6.2M |
| 4/2022 | Free Market Health | Series A | 0 |
| 10/2004 | Xelerated | Venture Round | 10M |
| 10/2010 | Pathwork Diagnostics | Series C | 30M |
| 7/2004 | Vitra Bioscience | Venture Round | 5.5M |
| 10/2003 | Cotherix | Series C | 55M |
| 4/2022 | Kelonia Therapeutics | Series A | 0 |
| 6/2007 | Kiadis Pharma | Venture Round | 0 |
| 7/2004 | Phenomix | Series A | 2M |
| 3/2015 | aTyr Pharma | Series E | 76M |
| 11/2012 | Applied Genetics Technologies Corporation | Series B | 0 |
| 4/2013 | Esperion | Venture Round | 33M |
| 7/2010 | Abionyx Pharma | Series C | 0 |
| 10/2019 | Variant Bio | Series A | 24.7M |
| 2/2004 | NeurogesX | Series C | 35M |
| 7/2018 | Qihan Biotech | Series A | 7.8M |
| 3/2008 | Trevena | Series A | 24M |
| 8/2018 | Everside Health | Private Equity Round | 165M |
| 5/2007 | Nanomix | Series D | 7.3M |
| 4/2000 | CornerHardware | Series B | 21M |
| 11/2007 | Excaliard Pharmaceuticals | Series A | 15.5M |
| 12/2012 | Larimar Therapeutics | Series D | 21M |
| 8/2005 | Abionyx Pharma | Series A | 30.5M |
| 1/2009 | Intradigm Corporation | Series B | 0 |
| 8/2004 | AGY Therapeutics | Series C | 9M |
| 3/2021 | DispatchHealth | Series D | 0 |
| 8/2001 | Eyetech Pharmaceuticals | Series C | 108.5M |
| 11/2005 | Portola Pharmaceuticals | Series B | 46M |
| 10/2010 | aTyr Pharma | Series C | 23M |
| 4/2003 | Rigel Pharmaceuticals | Post-IPO Equity | 46M |
| 6/2007 | Ceregene | Series C | 0 |
| 10/2004 | MacroGenics | Series B | 30.5M |
| 3/2021 | EGenesis | Series C | 0 |
| 4/2001 | Genteric | Series B | 22M |
| 4/2004 | Tacit Software | Venture Round | 7M |
| 9/2009 | aTyr Pharma | Series C | 12M |
| 5/2009 | Avid Radiopharmaceuticals | Series D | 0 |
| 7/2008 | Immune Design | Series A | 18M |
| 7/2022 | Everside Health | Private Equity Round | 164M |
| 3/2007 | Intarcia Therapeutics | Venture Round | 50M |
| 10/2020 | Transcarent | Series A | 40M |
| 3/2002 | Phenomix | Series A | 12M |
| 3/2004 | Insulet | Series D | 35.5M |
| 7/2010 | Immune Design | Series B | 32M |
| 2/2006 | Insulet Corporation | Series E | 0 |
| 5/2001 | Ceyba | Series B | 93M |
| 11/2004 | Netli | Venture Round | 8M |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 4/2005 | Sanarus Medical | Series D | 23M |
| 2/2007 | Sanarus Medical | Series E | 15M |
| 3/2014 | ZS Pharma | Series D | 0 |
| 9/2008 | Aegerion Pharmaceuticals | Convertible Note | 0 |
| 1/2008 | Sonexa Therapeutics | Series A | 0 |
| 3/2010 | TransMedics | Series E | 0 |
| 2/2000 | Terawave Communications | Series B | 0 |
| 5/2006 | Foldrx Pharmaceuticals | Series B | 43M |
| 11/2007 | Agami System | Series C | 50M |
| 5/2012 | Bioventus | Venture Round | 0 |
| 1/2022 | Transcarent | Series C | 0 |
| 6/2021 | Transcarent | Series B | 0 |
| 3/2021 | Tyra Biosciences | Series B | 106M |
| 9/2000 | TransMedics | Series A | 0 |
| 1/2006 | RedShift BioAnalytics | Series A | 12M |
| 9/2004 | Cellective Therapeutics | Series A | 27.5M |
| 5/2000 | eIndia | Venture Round | 0 |
| 1/2001 | Nanomix | Series A | - |
| 3/2011 | Aerie Pharmaceuticals | Series B | 41.4M |
| 2/2003 | Coapt Systems | Series C | 12.2M |
| 10/2001 | Xelerated | Series B | 12M |
| 7/2010 | Trevena | Series B | 35M |
| 12/2013 | Larimar Therapeutics | Series E | 45M |
| 8/2006 | Ablynx | Series C | 50M |
| 4/2005 | Phenomix | Series B | 20M |
| 7/2006 | USGI Medical | Series C | 21M |
| 9/2000 | Intarcia Therapeutics | Series C | 38M |
| 7/2000 | Cytos | Series B | 32M |
| 5/2001 | Anesiva | Series B | 13M |
| 8/2014 | Allakos | Series A | 24.5M |
| 4/2022 | Be Biopharma | Series B | 0 |
| 3/2017 | VertiFlex | Equity | 45.3M |
| 12/2004 | Intarcia Therapeutics | Series E | 50M |
| 11/2007 | Carbylan Therapeutics | Series B | 20M |
| 4/1999 | Intarcia Therapeutics | Series B | 12.1M |
| 6/2010 | Foldrx Pharmaceuticals | Venture Round | 29M |
| 5/2001 | Celetron International | Private Equity Round | 48M |
| 3/2007 | ChemGenex Pharmaceuticals | Series A | 16.4M |
| 9/2022 | Novome | Series B | 0 |
| 6/2008 | VertiFlex | Series C | 28.3M |
| 3/2007 | Calistoga Pharmaceuticals | Series A | 21M |
| 6/2020 | DispatchHealth | Series C | 135.8M |
| 6/2004 | ChemoCentryx | Series B | 33M |
| 9/2017 | DispatchHealth | Venture Round | 30.8M |
| 1/2007 | VertiFlex | Series B | 20M |
| 1/1999 | The Medicines Company | Venture Round | - |
| 12/2004 | Myocor | Series D | 24M |
| 12/2007 | Anesiva | Post-IPO Equity | 25M |
| 7/2022 | Everside Health | Venture Round | 0 |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 4/2022 | Kelonia Therapeutics | Series A | 0 |
| 4/2022 | Free Market Health | Series A | 0 |
| 4/2022 | Be Biopharma | Series B | 0 |
| 1/2022 | Transcarent | Series C | 0 |
| 6/2021 | ImmuneID | Series A | 0 |
| 6/2021 | Transcarent | Series B | 0 |
| 3/2021 | Tyra Biosciences | Series B | 0 |
| 3/2021 | DispatchHealth | Series D | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
